@alphavestcap $nwbo facebook.com/share/r/1KMsict… (Czerniecki discusses) x.com/exosome/status/2119579… x.com/alphavestcap/status/21… DATA TO BE RELEASED AT SNO FOR THESE THREE NWBO TRIALS. IS THERE A FOURTH ON OVARIAN RESULTS ? 1)(52)clinicaltrials.gov/study/NCT…. . 2) clinicaltrials.gov/study/NCT… (73) 3) clinicaltrials.gov/study/NCT… (47) virtual.oxfordabstracts.com/… jitc.bmj.com/content/14/Supp… clinicaltrials.gov/study/NCT… clinicaltrials.gov/study/NCT… x.com/d_stock07734/status/21… dc-cells-2026.p.asnevents.co… x.com/alphavestcap/status/21… x.com/alphavestcap/status/21… x.com/alphavestcap/status/21… x.com/d_stock07734/status/21…

richdag $nwbo @alphavestcap sunday, November 08, 2026 3:42:01 PM CA voters approved $8.4 Billion for immune system research in the recent election. Proposition 38 was endorsed by Dr. Linda Liau and is titled the "California Immunology Research and Cures Initiative". Prop. 38 authorizes up to $8.4 billion in state bonds for research on immune-system diseases and treatments. Likely beneficiaries include UCLA (can you spell Linda Liau) and other UC-affiliated and nonprofit researchers. Prior to the election Dr. Linda Liau's endorsement appeared in an October 26 press release from the Yes on 38 campaign. Linda Liau, M.D., Ph.D., MBA, is identified as Professor and Chair of Neurosurgery at the UCLA David Geffen School of Medicine, and is quoted calling immunology and immunotherapy research one of the most transformative frontiers in modern medicine. Seems to me this bodes quite well for some deep-well funding for Linda's further DCVax research! I'm aware of this because I voted in favor of Prop. 38 a few days ago. I also have accumulated over 200 individual tax lots of NWBO starting 12/28/2016, and have sold none of them. I won't say how many shares are currently held, except to say the total number consists only of 8's, all strung together, and there are at least 6 of them in the row. (And yes, I have a current Fidelity document showing that number).

$nwbo @alphavestcap investorshub.advfn.com/board… x.com/alphavestcap/status/21… investorshub.advfn.com/board… x.com/alphavestcap/status/21… investorshub.advfn.com/board…

$nwbo @alphavestcap pgsd friday, November 06, 2026 2:48:21 AM I find this very interesting. From a notice dated 06/25/2026: Government Owned Inventions Available for License: - NIH seeking partners/licensees to enhance the efficacy of dendritic cell (DC)-based cancer vaccines federalregister.gov/document… Government Owned Inventions Available for License: Compositions and Methods for Producing Dendritic Cell-based Vaccines With Enhanced Efficacy: Microsoft AI Analysis: This NIH/NCI notice is quite interesting from a DCVax perspective, although investors should be careful not to overstate what it means. What the NIH notice actually says The National Cancer Institute is offering for licence a patented technology that enhances dendritic cell (DC) vaccines by generating dendritic cells in the presence of omega-3 fatty acids (DHA/EPA) or specialised pro-resolving lipid mediators. According to the notice, this improves: Dendritic cell lifespan Antigen presentation Anti-tumour activity Overall vaccine potency The technology is currently at pre-clinical (in vivo validation) stage and has shown: Enhanced antigen-presenting function Significant tumour reduction in animal studies Improved survival in animal models compared with standard DCs Synergy with DCVax DCVax is fundamentally a dendritic cell vaccine platform. Therefore any technology that improves the functional quality of dendritic cells is, at least conceptually, relevant. Areas of potential synergy include: 1. Enhanced dendritic cell manufacturing The NIH invention focuses on how the dendritic cells are produced before administration. DCVax-L already involves: Leukapheresis Isolation of monocytes Ex-vivo differentiation into dendritic cells Tumour antigen loading Re-administration to the patient The NIH technology appears directed at improving the biological fitness of the dendritic cells during that manufacturing process. If translatable to humans, it could theoretically be incorporated into a DCVax-type workflow. 2. Improved antigen presentation One of the key determinants of efficacy in any dendritic-cell therapy is antigen presentation to T-cells. The NIH specifically reports enhanced antigen-presenting function. Since DCVax relies on dendritic cells presenting tumour antigens to activate anti-cancer immune responses, improvements here would be directly aligned with the platform's mechanism. 3. Overcoming tumour-induced immune suppression The NIH technology was developed because cancers create lipid imbalances and immunosuppressive conditions that impair dendritic-cell function. The notice states that omega-3-derived approaches may restore DC function under those conditions. If that translates clinically, it could potentially strengthen vaccine performance in difficult tumour microenvironments, which is a challenge across the entire dendritic-cell vaccine field. Possible positive implications for DCVax and NWBO Validation of the field The most immediate positive is not necessarily commercial but scientific. A major U.S. government cancer research organisation is publicly: Promoting dendritic-cell vaccine technology Seeking development partners Filing patents around improving DC vaccine efficacy That can be viewed as further validation that the dendritic-cell vaccine space remains an active area of research and commercial interest. Potential platform upgrades If technologies like this prove clinically relevant, DCVax's manufacturing process could theoretically be enhanced over time through: Licensing Collaboration Internal development of analogous approaches This is especially important because autologous cell therapy platforms often improve incrementally through manufacturing optimisation rather than complete redesign. Franchise expansion The notice specifically mentions: Human DC vaccines Cancer immunotherapy broadly Formulations involving omega-3 fatty acids and pro-resolving lipids If a company possessed a mature, scalable dendritic-cell manufacturing infrastructure, enhancements that improve DC potency could potentially be applied across multiple indications rather than a single tumour type. For a platform company, that is generally more attractive than a single-product opportunity. Bottom-line assessment From a DCVax viewpoint, I would characterise this as scientifically encouraging Further validation of dendritic-cell vaccines as an important immunotherapy modality. A potentially complementary technology focused on improving DC quality and potency. Conceptual applicability across dendritic-cell platforms, including DCVax. Evidence that NCI continues to invest intellectual property and research effort into the DC vaccine field. x.com/peter_brit/status/2118…

@alphavestcap fincen.gov/system/files/2026… cnbc.com/2026/10/13/bank-of-… ofac.treasury.gov/media/9372…

$NWBO @alphavestcap DATA TO BE RELEASED AT SNO FOR THESE THREE NWBO TRIALS. IS THERE A FOURTH ON OVARIAN RESULTS. 1)(52)clinicaltrials.gov/study/NCT…. . 2) clinicaltrials.gov/study/NCT… (73) 3) clinicaltrials.gov/study/NCT… (47) virtual.oxfordabstracts.com/… jitc.bmj.com/content/14/Supp… clinicaltrials.gov/study/NCT… clinicaltrials.gov/study/NCT… x.com/d_stock07734/status/21… dc-cells-2026.p.asnevents.co… x.com/alphavestcap/status/21… x.com/alphavestcap/status/21… x.com/alphavestcap/status/21… x.com/d_stock07734/status/21…

x.com/d_stock07734/status/21… @alphavestcap $nwbo

@alphavestcap $nwbo ANSWER: $20 BILLION.(current market cap $300 million) Assuming MAA approval (see below), what other events does that catalyze? Assuming those, what are the bid prices for $nwbo ? -two large combo partnerships(combo trials , plus up- front, non-dilutive cash. -Saudi definitive agreement -North American manufacturing (x.com/alphavestcap/status/21…), with BLA accepted "I think that all the t's and i's are crossed and dotted...it's just a case of the announcement by the MHRA and the company, and the timing of such???? In my personal opinion, Amanda and Braelyn would not have been given such a prestigious honor supported by the NHS if the approval was not known to be coming...it's all about orchestration...particularly as the First Secretary, Louise Haigh, put the onus on the Health Secretary and the Prime Minister in the House of Commons at PM question time." x.com/alphavestcap/status/21… x.com/alphavestcap/status/21… x.com/alphavestcap/status/21… x.com/alphavestcap/status/21… x.com/ATLnsider/status/21090…